Lyell Immunopharma (NASDAQ:LYEL) versus Aktis Oncology (NASDAQ:AKTS) Financial Review

Aktis Oncology (NASDAQ:AKTS – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Valuation and Earnings

This table compares Aktis Oncology and Lyell Immunopharma”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aktis Oncology $6.50 million 136.04 -$63.73 million ($1.36) -12.06
Lyell Immunopharma $40,000.00 8,348.31 -$274.45 million ($12.56) -1.08

Aktis Oncology has higher revenue and earnings than Lyell Immunopharma. Aktis Oncology is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Aktis Oncology and Lyell Immunopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aktis Oncology 1 0 9 1 2.91
Lyell Immunopharma 1 1 6 1 2.78

Aktis Oncology currently has a consensus target price of $35.62, suggesting a potential upside of 117.23%. Lyell Immunopharma has a consensus target price of $40.00, suggesting a potential upside of 194.55%. Given Lyell Immunopharma’s higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Aktis Oncology.

Insider and Institutional Ownership

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 66.0% of Lyell Immunopharma shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aktis Oncology and Lyell Immunopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aktis Oncology -706.81% -26.86% -18.13%
Lyell Immunopharma -1,701,066.75% -107.62% -80.01%

Summary

Aktis Oncology beats Lyell Immunopharma on 8 of the 12 factors compared between the two stocks.

About Aktis Oncology

(Get Free Report)

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

About Lyell Immunopharma

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.

Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.